Ipsen: collaboration agreement with Accent
(CercleFinance.com) - Ipsen announces that it has signed an exclusive worldwide collaboration agreement with Accent Therapeutics for the research, development, manufacturing and commercialisation of Accent's METTL3 inhibitor program.
The METTL3 enzyme is an RNA-modifying protein that has been validated in a pre-clinical phase as a novel therapeutic target to treat acute myeloid leukaemia (AML), a difficult-to-treat blood and bone marrow cancer.
Under the terms of the agreement, the pharmaceutical company will pay Accent up to 446 million dollars, including milestone payments, and tiered royalties on net sales.
Copyright (c) 2021 CercleFinance.com. All rights reserved.
The METTL3 enzyme is an RNA-modifying protein that has been validated in a pre-clinical phase as a novel therapeutic target to treat acute myeloid leukaemia (AML), a difficult-to-treat blood and bone marrow cancer.
Under the terms of the agreement, the pharmaceutical company will pay Accent up to 446 million dollars, including milestone payments, and tiered royalties on net sales.
Copyright (c) 2021 CercleFinance.com. All rights reserved.